You are here

CTD Holdings to Present at Brains for Brain Conference on Lysosomal Storage Diseases

Annual conference offers opportunities for academic researchers and industry representatives to exchange information on novel therapeutic interventions

ALACHUA, Fla., Dec. 10, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced its presentation at the annual Brains for Brain conference held under the auspices of the European Task Force on Brain and Neurodegenerative Lysosomal Storage Diseases (LSDs). The conference brings together academic researchers and industry representatives from around the world to discuss advances in the understanding neurodegeneration in LSDs and prospects for treatments and cures. The conference includes sessions on mechanisms to deliver therapeutics across the blood-brain-barrier. The conference will be held in Frankfurt, Germany between January 24–26, 2019.

CTD’s presentation, “Update on CTD’s Clinical Program”, will be made by Sharon H. Hrynkow PhD, Senior Vice President for Medical Affairs. The presentation will take place:

Saturday, January 26, 10:40 am
Hotel Mercure, Frankfurt Airport
Frankfurt, Germany            

Dr. Hrynkow will discuss initial data from the company’s two clinical trials for Niemann-Pick Disease Type C (NPC), both of which  use intravenous Trappsol® Cyclo™, CTD’s proprietary formulation of hydroxypropyl beta cyclodextrin. CTD is nearing completion of enrollment for its US-based phase I trial, with sites in Oakland, California and Morristown, NJ (see ClinicalTrials.gov NCT02939547) and for its phase I/II trial with sites in the UK, Sweden and Israel (see ClinicalTrials.gov NCT02912793). A third study is also open, an Extension Study for the US trial, which allows eligible patients who have completed the US phase I study to continue to receive Trappsol® Cyclo™ until the drug receives market approval. The Extension Study allows patients to receive the drug at home or in the hospital setting.

Dr. Hrynkow’s presentation slides will appear on the CTD company website (www.ctd-holdings.com) on or before January 26.

About CTD Holdings:
CTD Holdings, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C, a rare and fatal genetic disease, on a compassionate use basis as well as in two ongoing formal clinical trials (Clinical Trials.gov NCT02939547 and NCT02912793). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company’s website: www.ctd-holdings.com

Safe Harbor Statement:
This press release contains “forward-looking statements” about the company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company’s future performance include the company’s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company’s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Investor/Media Contact: 
Sitrick and Company 

Wendy Tanaka 
(415) 369-8447 
wtanaka@sitrick.com 

Thomas Mulligan 
(212) 573-6100, Ext. 395 
tmulligan@sitrick.com

Monday, December 10, 2018 - 09:11